Cogent Biosciences

$11.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can buy or sell COGT and other stocks, options, and ETFs commission-free!

About COGT

Cogent Biosciences, Inc. Common Stock, also called Cogent Biosciences, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. The listed name for COGT is Cogent Biosciences, Inc. Common Stock.

CEO
Andrew R. Robbins
Employees
72
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
355.36M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
334.36K
High Today
$12.32
Low Today
$11.75
Open Price
$11.79
Volume
196.91K
52 Week High
$14.88
52 Week Low
$1.18

Collections

COGT Earnings

-$0.31
-$0.21
-$0.10
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, Pre-Market

You May Also Like

HYEM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure